CAS Number

624-49-7

Molecular Formula

Molecular Weight

144.13

Molecular Structure

Packing

25kg/drum

Capacity

20MT/M

Storage

Sealed tightly and stored away from light in a cool and dry place

Application

Since 2013, Dimethyl-Fumarate has been approved by the 

U.S. Food and Drug Administration (FDA) as a treatment 

option for adults with relapsing multiple sclerosis (brand name Tecfidera).

In 2017, a new oral formulation of dimethyl fumarate (trade name Skilarence) 

was approved by the European Medicines Agency (EMA) for use in the 

European Union as a treatment for moderate-to-severe plaque psoriasis.

Dimethyl fumarate is thought to have immunomodulatory properties without 

causing significant immunosuppression.

Dimethyl fumarate has also been applied as a biocide in furniture or shoes to prevent 

growths of mold during storage or transport in a humid climates. However, due to cases 

of allergic reactions after skin contact, dimethyl fumarate-containing consumer products 

are no longer authorised to be manufactured (since 1998) or imported (since 2009) in 

the European Union.Dimethyl fumarate is approved as a generic medication in the 

United States as of 2020.

Appearance

White or almost white crystalline powder

  Loss on Drying

≤0.5%

  Residue on Ignition

≤0.02%  

  Chromatographic Purity

    Single impurity≤0.1%

                             Total Impurities≤0.5%

 Assay(on dried basis)

 98.0 ～ 102.0%

Standard

USP/EP standard